A case of intravitreal bevacizumab injection for the treatment of choroidal neovascularization in angioid streaks

• Published in: Korean journal of ophthalmology 2011, 25(3), , pp.218-221
• Main Authors: Lee, Ji Woong, Shin, Jae Pil, Kim, Si Yeol
• Format: Article
• Language: English
• Subjects: Angiogenesis Inhibitors - administration & dosage; Angioid Streaks - complications; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Bevacizumab; Case Report; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Choroidal Neovascularization - physiopathology; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea - drug effects; Macula Lutea - pathology; Middle Aged; Tomography, Optical Coherence; Visual Acuity - drug effects; 안과학
• ISSN: 1011-8942; 2092-9382
• DOI: 10.3341/kjo.2011.25.3.218

A 56-year-old Korean woman presented with decreased visual acuity of the right eye. She had a history of two photodynamic therapy treatments for choroidal neovascularization (CNV) due to angioid streaks in her left eye with central scarring and low visual acuity. She was diagnosed with subfoveal CNV due to angioid streaks in her right eye and treated with six intravitreal bevacizumab (1.25 mg / 0.05 mL) injections over one year. Best corrected visual acuity improved from 20 / 125 at baseline to 20 / 50 at the final visit. The area of CNV had changed into a fibrotic scar by the final visit, and fluorescein angiography and indocyanine green angiography revealed no evidence of leakage. Optical coherence tomography showed that central macular thickness decreased from 311 µm at baseline to 203 µm with complete resolution of subretinal and intraretinal fluid at the final visit. Intravitreal bevacizumab for CNV associated with angioid streaks prevented the progression of disease and resulted in the improvement of visual acuity after one year of follow-up in our patient.